ARON AIZENSTAT, MBA, PMP

Head of Business Development & Corporate Strategy

📞 305.586.5514 🛛 @ aaizenstat11@gmail.com Attps://www.linkedin.com/in/aronaizenstat/ Q Coral Gables, FL

SELECTED ACCOMPLISHMENTS

- Sold NDA-ready sofpironium bromide program for \$177 million in upfront cash and future payments, followed by subsequent cash buyout.
- Closed strategic partnership with Fosun Pharma for TEV-56278, a novel anti-PD1-IL2 ATTENUKINE immunotherapy, in Greater China to advance Teva's innovative pipeline.
- Acquired > 1,000 novel compounds for immunology, neurodegenerative, oncology, and rare diseases from global partners for \$580 million total deal value.
- Executed corporate shift in strategy from dermatology to immunology, including global search & evaluation (S&E) of > 500 novel programs.
- · Managed sofpironium bromide Asia co-development partnership with successful completion of 20+ clinical trials, 50+ nonclinical studies & 12+ manufacturing campaigns.
- Successfully managed 15 strategic alliances with licensors and global strategic partners.
- Divested out-of-scope VL-2397 for \$25 million in upfront cash and future payments.
- Coordinated with R&D successful completion of pivotal Phase 3 clinical program for sofpironium bromide and preparation and submission of US-NDA with the FDA.

PROFESSIONAL EXPERIENCE

Senior Director, Business Development 08/2024 - Present Teva Pharmaceuticals (NYSE: TEVA) Parsippany, NJ • Responsible for all global BD efforts within immunology core therapeutic area. Led selection, design and build of enterprise-wide deal database, enabling continuous tracking and real-time reporting of all companies, assets, deals and interactions. Developed and launched comprehensive S&E process for innovative immunology assets, enabling systematic screening of 1,000+ opportunities aligned with strategic priorities. 02/2024 - Present Managing Member Miami, FL **BIOGENAYA, LLC** · Provide BD and corporate strategy consulting services to biotech and pharma companies. VP, Corporate Development & Operations 01/2022 - 02/2024 Boulder, CO Fresh Tracks Therapeutics, Inc. (NASDAQ: FRTX) • Responsible for BD, corporate strategy, program & alliance management, IR, corporate communications and business operations functions. • Led formal strategic alternatives process with > 125 possible partners to assess sale, merger, financing or licensing of assets prior to wind down of Company. • Created robust deal tracking system to manage all BD interactions & negotiations. • Recruited, hired and managed Senior Manager, Program & Alliance Management leading to enhanced productivity and project execution. Oversaw successful completion of Phase 1 clinical trial for lead DYRK1A inhibitor program and advancement of preclinical STING inhibitor program to IND-enabling studies. Business lead on all SEC filings, NASDAQ compliance and IP prosecution. 06/2020 - 01/2022 Senior Director, Corporate Development & Operations Boulder, CO Fresh Tracks Therapeutics, Inc. (NASDAQ: FRTX) · Co-led international BD expansion project to partner sofpironium bromide in North America, EU, LATAM, Middle East and Africa. • Supported litigation, arbitration and win-win settlement of licensor dispute for sofpironium bromide. • Led planning, execution and launch of corporate rebrand from BBI to FRTX. Senior Project & Operations Manager 05/2016 - 06/2020 Brickell Biotech, Inc. (NASDAQ: BBI) Miami FI • Supported Management in effort to go public via triangular reverse merger. • Led multiple scale-up manufacturing campaigns totaling > \$1 million at 5 different CMOs. Project Manager 05/2015 - 05/2016 Brickell Biotech, Inc. (NASDAQ: BBI) Miami, FL · Responsible for R&D planning and execution of all pipeline development activities. • Assisted management in development and oversight of corporate budget. Senior Business Intelligence Analyst 09/2014 - 03/2015 DLA, Inc. Miami, FL • Launched first Video-on-Demand platform in LATAM with > \$100M digital content.

• Managed global team of 90+ software developers spread across 4 continents.



EDUCATION

Master of Business Administration

University of Colorado at Boulder

• Class Rank: 3 of 80

B.A. in Chemistry w/ Scientific **Modeling Sequence**

Claremont McKenna College

OTHER

Board Member

Coral Gables Parks & Recreation Advisory Board 11/2023 - Present

SKILLS

- **Business Development**
- Corporate Strategy
- Search & Evaluation
- **Due Diligence**
- **Negotiations & Contracting**
- **Global Alliance Management**
- **Program Management**
- **Investor Relations**
- **Corporate Communications**
- **Public Company Operations**
- Intellectual Property
- **Platform Technologies**
- **Clinical Trials**
- Nonclinical Development
- Manufacturing
- Information Technology
- Software Development

PROFESSIONAL EXPERIENCE

Senior Business Analyst & Project Manager	03/2012 - 09/2014
Kaufman Rossin Fund Services, LLC Coached 10 developer team through > 300 new software features 8 	Miami, FL
Junior Fund Accountant	10/2011 - 03/2012
Kaufman Rossin Fund Services, LLC	Miami, FL
 Conducted net asset value reporting for 8 hedge funds with >\$500 million AUM. 	